Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections

Pediatr Infect Dis J. 2011 Aug;30(8):712-4. doi: 10.1097/INF.0b013e31820fc8e1.

Abstract

A pharmacokinetic analysis was performed for single intravenous doses of daptomycin 8 or 10 mg/kg in subjects aged 2 to 6 years. Proportional increases in maximum plasma concentration (68.4 μg/mL, 79.2 μg/mL) and area under the curve (429.1 μg · h/mL, 549.7 μg · h/mL) were observed for each dose cohort, respectively. Half-life, clearance, and distribution volume were similar between groups. Both doses were well tolerated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / pharmacokinetics*
  • Area Under Curve
  • Biological Availability
  • Child
  • Child, Preschool
  • Daptomycin / administration & dosage
  • Daptomycin / adverse effects*
  • Daptomycin / pharmacokinetics*
  • Female
  • Gram-Positive Bacterial Infections / drug therapy*
  • Half-Life
  • Humans
  • Injections, Intravenous
  • Male
  • Metabolic Clearance Rate
  • Plasma / chemistry

Substances

  • Anti-Bacterial Agents
  • Daptomycin